Non-vitamin K antagonist oral anticoagulants and the gastrointestinal bleeding risk in real-world studies

L Anghel, R Sascău, A Trifan, IM Zota… - Journal of clinical …, 2020 - mdpi.com
In the present study, we aimed to provide evidence from high-quality real world studies for a
comprehensive and rigorous analysis on the gastrointestinal bleeding (GIB) risk for non …

The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis

HJ Oh, KH Ryu, BJ Park, BH Yoon - Medicine, 2021 - journals.lww.com
Background: Non-vitamin K antagonist oral anticoagulants (NOACs) have been widely used
for stroke prevention in atrial fibrillation (AF) and the treatment and prevention of venous …

Risk of gastrointestinal bleeding in patients taking non–vitamin K antagonist oral anticoagulants: a systematic review and meta-analysis

CS Miller, A Dorreen, M Martel, T Huynh… - Clinical Gastroenterology …, 2017 - Elsevier
Background & Aims Non–vitamin K antagonist oral anticoagulants (NOACs) are convenient
and effective in the prevention and treatment of venous thromboembolism and the …

The association between non‐vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta‐analysis of observational studies

Y He, ICK Wong, X Li, S Anand… - British journal of …, 2016 - Wiley Online Library
Particular concerns have been raised regarding the association between non‐vitamin K
antagonist oral anticoagulants (NOACs) and the risk of gastrointestinal bleeding (GIB); …

Major gastrointestinal bleeding risk with direct oral anticoagulants: Does type and dose matter?–A systematic review and network meta-analysis

D Radadiya, K Devani, B Brahmbhatt… - European Journal of …, 2021 - journals.lww.com
The relative risk of major gastrointestinal bleeding (GIB) among different direct oral
anticoagulants (DOACs) is debatable. Randomized controlled trials (RCTs) comparing …

Gastrointestinal safety of direct oral anticoagulants: a large population-based study

NS Abraham, PA Noseworthy, X Yao… - Gastroenterology, 2017 - Elsevier
Background & Aims Direct oral anticoagulant (DOAC) agents increase the risk of
gastrointestinal (GI) bleeding. We investigated which DOAC had the most favorable GI safety …

Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants: A nationwide propensity score–weighted study

AB Ingason, JP Hreinsson, AS Ágústsson… - Annals of Internal …, 2021 - acpjournals.org
Background: Gastrointestinal bleeding (GIB) rates for direct oral anticoagulants (DOACs)
and warfarin have been extensively compared. However, population-based studies …

Comparative differences in the risk of major gastrointestinal bleeding among different direct oral anticoagulants: An updated traditional and Bayesian network meta …

X Chen, L Wang, H Li, W Huang, L Zhao… - Frontiers in …, 2023 - frontiersin.org
Background: The most favorable gastrointestinal (GI) bleeding safety profile among different
types of direct oral anticoagulants (DOACs) remains controversial. This meta-analysis …

Safety of direct oral anticoagulants for gastrointestinal hemorrhage in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of real-world …

PA Barakakis, DG Kokkinidis, W Li… - Journal of Clinical …, 2023 - journals.lww.com
Results: A total of 46 studies were included. Apixaban was associated with a reduced risk of
GIH compared with Dabigatran (HR: 0.67, 95% CI, 0.56 to 0.81, I 2: 53.28%), Rivaroxaban …

Systematic review with meta‐analysis: the risk of major gastrointestinal bleeding with non‐vitamin K antagonist oral anticoagulants

D Caldeira, M Barra, A Ferreira, A Rocha… - Alimentary …, 2015 - Wiley Online Library
Background Gastrointestinal (GI) bleeding is a common complication among anticoagulated
patients. Non‐vitamin K antagonist oral anticoagulants (NOAC s) are associated with …